Document Detail

Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.
MedLine Citation:
PMID:  22906900     Owner:  NLM     Status:  In-Data-Review    
Platelets play a critical role in the pathophysiology of acute coronary syndrome and thromboembolic complications associated with atrial fibrillation. Despite the development of newer and more potent antiplatelet agents, aspirin remains the cornerstone of antithrombotic therapy. Clinical trials conducted over the past decades have clearly established the safety and efficacy of aspirin therapy for the acute treatment and secondary prevention of acute myocardial infarction, ischemic stroke, and vascular death among patients at high risk for cardiovascular events. Although the absolute benefit of aspirin for primary prevention is lower than seen in secondary prevention trials, it is nevertheless an accepted preventive. This chapter provides a comprehensive overview of the clinical utility of aspirin in the setting of acute coronary syndrome and atrial fibrillation.
Jean-François Tanguay
Publication Detail:
Type:  Journal Article     Date:  2012-08-09
Journal Detail:
Title:  Advances in cardiology     Volume:  47     ISSN:  0065-2326     ISO Abbreviation:  Adv Cardiol     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0270063     Medline TA:  Adv Cardiol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  20-30     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Que., Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of antiplatelet therapy in heart disease.
Next Document:  Clopidogrel in coronary artery disease: update 2012.